| 1/3/2013 | BKIG | Watson Pharmaceuticals readies for growth, new products, name change
|
| 10/1/2012 | IG | Market Commentary: Midday Commentary: Watson Pharmaceuticals' new notes firm to 33 bps; NBCUniversal tightens
|
| 9/28/2012 | IG | Market Commentary: Midday Commentary: NBCUniversal on tap as September nears record issuance, Watson tightens
|
| 9/28/2012 | IG | Market Commentary: NBCUniversal prices $2 billion issue to close out record month; Watson bonds trade tighter
|
| 9/27/2012 | CVIGPF | Watson files automatic shelf for stock, preferreds and debt securities
|
| 9/27/2012 | IG | Market Commentary: Midday Commentary: Watson, MetLife prep deals; bonds improve in trading as demand remains high
|
| 9/27/2012 | IG | New Issue: Watson Pharmaceuticals sells $3.9 billion of notes in five-, 10-, 30-year tranches
|
| 9/27/2012 | BKCVIG | Fitch lowers Watson
|
| 9/27/2012 | IG | Market Commentary: Watson prices mega deal for M&A; MetLife does remarketing; traders see appetite for corporates
|
| 9/27/2012 | BKCVIG | S&P rates Watson notes BBB
|
| 9/27/2012 | IG | Watson Pharmaceuticals talks about $3.75 billion of notes in five-, 10-, 30-year tranches
|
| 9/27/2012 | BKIG | Moody's: Watson notes Baa3
|
| 6/27/2012 | BKCVIG | Fitch rates Watson loan BBB
|
| 6/25/2012 | BK | Watson Pharmaceuticals gets $1.8 billion five-year loan to buy Actavis
|
| 5/23/2012 | BK | Watson Pharmaceuticals ups revolver to $750 million, modifies covenants
|
| 4/25/2012 | BKIG | Watson plans to fund €4.25 billion acquisition with term loan, notes
|
| 4/25/2012 | CVIG | Moody's: Watson view stable
|
| 4/25/2012 | IG | Fitch: Watson on watch
|
| 4/25/2012 | IG | S&P: Watson view to negative
|
| 1/24/2012 | BK | Watson uses credit facility borrowings to fund Ascent acquisition
|
| 1/24/2012 | IG | S&P: No change to Watson
|
| 9/19/2011 | BK | Watson wraps $500 million revolving facility at Libor plus 125 bps
|
| 8/5/2011 | IG | Fitch affirms Watson Pharma
|
| 5/25/2011 | IG | Fitch: Watson unchanged
|
| 5/25/2011 | IG | S&P affirms Watson
|
| 5/25/2011 | IG | Moody's: Watson unchanged
|
| 3/11/2011 | IG | Moody's ups Watson to positive
|
| 8/9/2010 | CVIG | Fitch ups Watson Pharmaceuticals
|
| 6/8/2010 | CVHY | Moody's lifts Watson from junk
|
| 9/24/2009 | HY | Market Commentary: DISH, Spirit deals price; Tops plans offering; Delta coupon grows; funds gain $317 million
|
| 9/21/2009 | HY | Market Commentary: ACCO deal prices, moves up, existing bonds pop also; Sprit Aero, Nebraska Book slate deals
|
| 9/8/2009 | HY | Market Commentary: Junk primary back with Harrah's, Plains; Smithfield ignores numbers, AIG ignores asset sale
|
| 9/2/2009 | HY | Market Commentary: Beazer bounces as company shops new deal; Blockbuster better on liquidity move; Freeport firm
|
| 9/1/2009 | HY | Market Commentary: Beazer plans deal, Warner Chilcott is fall's 'big one'; DirecTV active, Asarco zooms on ruling
|
| 8/28/2009 | CV | Market Commentary: AMD extends gains after Intel raises forecast; Intel also higher; E*Trade active after swap deal
|
| 8/26/2009 | HY | Market Commentary: Kodak, Smurfit among gainers, Isle of Capri off on numbers; primary set for September surge
|
| 8/25/2009 | CV | Watson announces redemption of 1.75%, variable-rate convertibles
|
| 8/25/2009 | HY | Market Commentary: Michaels up on numbers, CIT active as broad market quiet; Warner Chilcott details bond plans
|
| 8/24/2009 | HY | Market Commentary: New Watson still trades around, junk otherwise quiet; Warner Chilcott plans bonds
|
| 8/21/2009 | IG | Market Commentary: High-grade bond sales halt despite good tone; new industrials improve; AmEx Credit gains
|
| 8/21/2009 | HY | Market Commentary: New Watson bonds continue strong in trading; Sinclair up despite subordination in debt deal
|
| 8/20/2009 | HY | Market Commentary: Bon-Ton bounces on better EBITDA, outlook; AIG up on CEO pledge; funds lose $90 million, end seven-week run
|
| 8/20/2009 | IG | Market Commentary: Yum!, News America, AmEx Credit offer bonds, tone recovers; financials wider, Watson gains
|
| 8/19/2009 | CV | Market Commentary: Johnson Controls rises to well above double par; D.R. Horton slips; Watson, Saks active
|
| 8/19/2009 | HY | Market Commentary: CIT Canada, American Axle calm down after Tuesday jump; Smithfield suffers; new deals nowhere
|
| 8/19/2009 | IG | Market Commentary: Viacom upsizes sale, R.R. Donnelley offers bonds, tone weakens; recent deals widen in trading
|
| 8/18/2009 | CV | Watson plans to redeem convertibles, pay down portion of term loan
|
| 8/18/2009 | CV | Market Commentary: Allegheny Technologies trades lightly; Saks mostly flat after smaller-than-expected loss
|
| 8/18/2009 | HY | Market Commentary: CIT Canada is busiest junk name; American Axle jumps on GM aid; split-rated Watson only deal
|
| 8/18/2009 | BK | Watson Pharmaceuticals to repay $100 million in term loan borrowings
|
| 8/18/2009 | HYIG | New Issue: Watson Pharmaceuticals sells $850 million split-rated five-, 10-year senior notes
|
| 8/18/2009 | BKCV | Moody's affirms Watson
|
| 8/18/2009 | IG | Market Commentary: RBS, Boardwalk, Sierra Pacific, Air Products sell bonds on upbeat tone; Watson prices, gains
|
| 8/18/2009 | BKCV | Fitch affirms Watson
|
| 8/17/2009 | CVIG | Watson files automatic shelf for debt securities, preferreds and stock
|
| 7/27/2009 | CV | Market Commentary: Ford careens higher; Webster boosted by PIPE investment; Mylan mostly firm as shares drop
|
| 7/7/2009 | BK | Watson amends to permit up to $500 million in general unsecured debt
|
| 6/18/2009 | BKCV | Fitch affirms Watson
|
| 6/18/2009 | CV | Market Commentary: Whiting Petroleum slips below par on debut; Watson up; newly priced issues in focus
|
| 6/17/2009 | BKBWCVSS | Watson may refinance convertibles to help fund Arrow acquisition
|
| 6/17/2009 | BKCV | Moody's: Watson loans on review uncertain
|
| 6/17/2009 | SS | Market Commentary: Watson to buy Arrow; Trump makes bid for Trump Entertainment casinos; Broadcom offer expires
|
| 5/26/2009 | BKCV | Moody's: Watson outlook positive
|
| 4/22/2009 | CV | Market Commentary: Watson, OSI add on buyout rumors; Alexandria up; Ford jumps, GM mixed; Old Republic to price
|
| 3/3/2009 | CV | Market Commentary: Ford lower, GM mixed; financials, Prudential under pressure; Watson Pharmaceuticals stronger
|
| 2/19/2009 | CV | Market Commentary: Financials extend losses; Wells Fargo preferreds sink to 400; Watson in focus after better earnings
|
| 11/25/2008 | CV | Market Commentary: Merrill Lynch sees better buyers; Ford adds, but GM mixed; Charming Shoppes, Watson edge higher
|
| 11/25/2008 | SS | Watson Pharmaceuticals to acquire generic products following merger of Teva, Barr
|
| 10/27/2008 | IG | Fitch affirms Watson
|
| 3/18/2008 | IG | S&P ups Watson outlook to stable
|
| 2/25/2008 | BK | Watson Pharmaceuticals repays $75 million of bank debt
|
| 10/29/2007 | IG | Fitch affirms Watson
|
| 3/1/2007 | CV | S&P: Watson Pharmaceuticals unaffected
|
| 11/6/2006 | BTCV | Fitch cuts Watson to BBB-
|
| 11/6/2006 | BK | Market Commentary: Freescale, RSC, Energy Transfer set talk; Greenwood cuts pricing; Per-Se softer on buyout news
|
| 10/9/2006 | BT | Jefferies: CollaGenex, Forest Labs beat Q3 estimates; Connetics lags behind
|
| 9/21/2006 | BKBTCVHY | Moody's revises ratings for nine U.S. pharma companies
|
| 9/13/2006 | BT | Unimed, Watson, Par settle AndroGel testosterone gel patent litigation
|
| 9/7/2006 | BT | Watson: FDA approves generic contraceptive to be launched as Quasense
|
| 8/4/2006 | BKBTCVHY | S&P rates Watson Pharmaceuticals loan BBB-, lowers notes to BB+
|
| 8/4/2006 | BKBTCVHY | Moody's cuts Watson Pharmaceutical convertibles to Ba2, rates loans Ba1
|
| 7/31/2006 | BT | Warner Chilcott files patent infringement suit against Watson Pharmaceuticals
|
| 7/17/2006 | BKBT | Watson Pharmaceuticals sets Wednesday launch for $1.15 billion credit facility
|
| 7/10/2006 | BT | Watson, Andrx extend deadline for close of merger to allow for FTC review
|
| 6/23/2006 | BT | Warner Chilcott says Watson seeks generic Loestrin
|
| 6/1/2006 | BT | Watson gets approval for generic pregnancy-prevention drug
|
| 5/10/2006 | BTCV | S&P keeps Watson on negative watch
|
| 5/9/2006 | BT | Watson Pharmaceuticals receives tentative approval from FDA for generic Seasonale
|
| 5/9/2006 | CV | Market Commentary: SanDisk deal gains in gray market; Broadwing offering seen as fair; General Motors mixed on upgrade
|
| 5/3/2006 | BT | Federal Trade Commission requests more information in Watson's acquisition of Andrx
|
| 4/25/2006 | BT | Watson begins distribution of generic Pravachol
|
| 3/30/2006 | BT | Watson Pharmaceuticals to divest Arizona facility
|
| 3/29/2006 | CV | Market Commentary: Lear gains on financing news, Amdocs strengthens; new issue from AMG fails to enthuse
|
| 3/15/2006 | BKBTCV | Moody's may downgrade Watson
|
| 3/15/2006 | BKBT | Watson Pharmaceuticals outlines structure on $1.15 billion facility
|
| 3/14/2006 | BT | Watson gets neutral rating from Credit Suisse
|
| 3/14/2006 | CV | Market Commentary: Fair Isaac plunges on fears of new rival product; Human Genome slides on mixed trial results
|
| 3/13/2006 | BT | Watson Pharmaceuticals to acquire Andrx for $1.9 billion
|
| 3/13/2006 | BKBT | Watson Pharmaceuticals to get $1.15 billion in bank debt for Andrx purchase
|
| 3/13/2006 | BTCV | S&P puts Watson on negative watch
|
| 3/13/2006 | BTCV | Fitch puts Watson on negative watch
|
| 3/13/2006 | BT | Watson cut to neutral by Credit Suisse
|
| 3/13/2006 | CV | Market Commentary: Lear surges on rumored refinancing; Apex Silver slides on probe; Watson falls on takeover
|
| 3/13/2006 | BT | Market Commentary: NitroMed off on data; NPS gains 7%; Vasogen falls on trial failure; Medicines up 10%; Myriad higher
|
| 3/7/2006 | BKBT | Watson Pharmaceuticals amends loan, allowing for stock repurchases
|
| 2/23/2006 | BTCV | Fitch affirms Watson
|
| 1/30/2006 | BT | Watson Pharmaceuticals gets FDA OK for generic testosterone gel
|
| 1/5/2006 | CV | Market Commentary: Convertible market extends broad-based gains; autos, biotechs lift; Fannie Mae adds
|
| 12/9/2005 | BT | Market Commentary: Adams slides after secondary; Voyager IPO delayed; Cephalon spikes, Teva rises; Genitope up
|
| 12/9/2005 | CV | Market Commentary: Cephalon, Teva gain on patent settlement; eyes turn toward Omnicare; Alltel mostly quiet
|
| 11/16/2005 | BT | S&P ups Watson Pharmaceuticals outlook to stable
|
| 11/4/2005 | BT | Market Commentary: Introgen's stock lifts on Colgate-Palmolive alliance; Cytori, Olympus enter into joint venture
|
| 11/4/2005 | CV | Market Commentary: Qwest, Chesapeake remain active; Celgene up, Emdeon lower; King sideways
|
| 11/3/2005 | CV | Market Commentary: Chesapeake, Qwest trade higher; Abgenix, Amgen rise, but ImClone lower; SFBC plunges
|
| 10/19/2005 | BT | Citigroup ups price target on Watson Pharmaceuticals
|
| 9/13/2005 | BT | Watson Pharmaceuticals buys back $300 million shares
|
| 9/2/2005 | BT | Market Commentary: Cell Therapeutics plunges on auditor departure; Amylin shares off on profit taking; Watson off
|
| 8/19/2005 | BT | Market Commentary: Quintiles tapping bond market for $150 million; Merck spirals on Vioxx verdict; Vyteris taps PIPEs
|
| 8/1/2005 | BT | Market Commentary: Anadys, Ariad, Nastech offerings join ZymoGenetics for this week; Amgen, Abgenix up on fast track
|
| 7/19/2005 | BT | S&P: U.S. generic drug industry entering more challenging period; Alpharma, Mylan, Teva, Watson at risk
|
| 7/7/2005 | CV | Market Commentary: Biotechs up as convertibles find footing after early dip; airlines down; some oil and gas names extend gains
|
| 7/1/2005 | BT | Market Commentary: Altana crushed by Pfizer news; Cubist, Corixa rise in thin market, Millennium off; Cephalon higher
|
| 10/25/2004 | CV | Market Commentary: Armor overnighter slips in gray market; Isolagen, Option Care deals also emerge
|
| 8/30/2004 | CV | Market Commentary: LNR convertible leveled by $1.9 billion cash takeover; United Rentals falls on SEC inquiry
|
| 7/7/2004 | CV | Market Commentary: Omnicom, AMG spiral on new CoCo rule possibility; EDS active on tighter credit
|
| 7/1/2004 | BKCV | S&P: Watson outlook negative
|
| 7/1/2004 | BKCV | Moody's affirms Watson
|
| 6/30/2004 | CV | Market Commentary: Market watches Fed; Allscripts, General Mills and Watson Pharmaceuticals trade
|
| 6/29/2004 | CV | Market Commentary: New liquid paper seen as a nice addition for traders although some sit back waiting on Fed meeting
|
| 3/22/2004 | CV | Fitch upgrades Watson
|
| 12/2/2003 | CV | Fitch: Some issuers may improve balance sheet, ratings with convertibles conversion
|
| 9/25/2003 | CV | Market Commentary: Pharma Resources gains to 104 despite complaint; Bristol-Myers jumbo seen offered at par in gray
|
| 9/24/2003 | CV | Market Commentary: CKE bids beefed up to 107; Flextronics expected to lose "big points" on jury award
|
| 6/2/2003 | BK | Market Commentary: Qwest upsizes, Charter and Nextel firm in trading
|
| 3/24/2003 | CV | Fitch ups GTech outlook
|
| 3/10/2003 | CV | Market Commentary: Interpublic again dominates market attention; new paper weak amid sluggish session
|
| 3/6/2003 | CV | Market Commentary: Raytheon dives on pension costs; some retail issues find buyers on recent weakness
|
| 3/5/2003 | BK | Shiloh Industries reduces bank debt by over $60 million
|
| 3/5/2003 | CV | Fitch rates Watson convert BBB-
|
| 3/5/2003 | CV | Market Commentary: Watson trades up out of gate, Provident plunges, call scare ripples throughout market
|
| 3/5/2003 | CV | New Issue: Watson upsizes convertibles to $500 million, yield 1.75%, up 42%
|
| 3/4/2003 | CV | Market Commentary: Inco deals steady out of gate; Watson trading up in gray as credit, put offset pricey terms
|
| 3/4/2003 | BK | Watson Pharmaceuticals gets commitment for $300 million revolver
|
| 3/3/2003 | CV | Moody's ups American Tower liquidity rating
|
| 3/3/2003 | CV | Market Commentary: Inco prices $400 million, Watson launches quickie; Capital One dives on CFO departure
|
| 3/3/2003 | CV | Watson launches $450 million convertibles talked at 1.75-2.25%, up 38-42%
|
